The Senior Manager, Market Control of the South African Health Products Regulatory Authority (SAHPRA) Mokgadi Daphne Fafudi (pictured here), has confirmed that the regulator has decided to review the way Section 21 is being used to access cannabis.
She says that halting authorizations has been part of this review but that the intention was not to deprive genuine medical cannabis patients their treatment.
Speaking at an online webinar organized by the Southern African Pharmaceutical Regulatory Affairs Association ( SAPAA – not to be confused with SAHPRA), Fafudi said that had been widespread abuse of Section 21 by people seeking access to cannabis for non-medical purposes. Section 21 of the Medicines Act, which allows for doctors to prescribe a medicine for a treatment for which there is no registered alternative available.
Addressing the issue in public for the first time since SAHPRA halted all Section 21 authorizations in July 2026, Fafudi said:
“There has been a review of the current situation. This mechanism is meant to be highly restricted. Through monitoring we have picked up evidence that it has been misused”.
She said this was the reason SAHPRA pulled the plug on Section 21. But she said that patients seeking Section 21 approval for genuine medical conditions could still get the go-ahead in the interim.
“With proper evidence-based submissions, such applications will still be considered” she said.
Fafudi said that cannabis approved under Section 21 was being “commercialized” and despite it being a Schedule 6 drug, it was ending up on the streets. Outlets claiming to have SAHPRA approval were openly selling cannabis in defiance of the law, she said.
Fafudi said SAHPRA’s role was to ‘ensure public safety’ and to this end was working with SAPS to close down all illegal cannabis outlets claiming to be operating with the regulator’s permission.
“Section 21 has to be reviewed. There are products that are appearing in shopping malls and informal markets that claim to be authorized to sell Section 21 cannabis, but this is not the case” she said. “We will never issue permits for a scheduled medicine to be available for sale in shopping centres”.
“We will work with the police to have these shops put down” she said. “A private retailer cannot sell medicine”.
She admitted that law enforcement was cumbersome as SAHPRA inspectors could act against people contravening the Medicines Act, but that enforcement had to be done by SAPS via the Criminal Procedures Act.
Fafudi did not address the many questions from the 163 webinar attendees on Section 21, but said the regulator was planning a stakeholder webinar to address this issue. She also gave no further details on what the Section 21 review entailed or how long it would take.
#






